News | July 28, 2023
Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Subscribe To Our Newsletter & Stay Updated
